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Summary The prevalence of congenital heart disease among adults in Europe, or in any coun-
try in Europe, is not known. This is due to a lack of agreement on the incidence of congenital
heart disease, with estimations varying from four per 1000 births to 50 per 1000 births, and it is
not known how many patients with congenital heart disease have died. Based on several studies
that estimated and calculated the number of adult patients with congenital heart disease, the
number of patients should be much higher than the number of patients that are actually seen
in specialized centres throughout Europe. This implies that either a large proportion of adult
patients with congenital heart disease do not receive appropriate medical care, or that the
calculations and estimations are grossly wrong. A combination of the two is also possible. A
substantial expansion of the number and size of specialized centres for adult congenital heart
disease is advocated, but since setting up (and running) a service for this disease is a costly
affair, and because uncertainty remains about the actual number of patients needing specialized
care, this has been difﬁcult to realize in most European countries in the past few years.
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Résumé La cardiopathie congénitale est la principale étiologie des défects congénitaux. En
terme d’organisation des soins, l’impact des cardiopathies congénitales dans les premières
années de la vie a surtout été mis en avant. Avant l’ère de la chirurgie cardiaque, les
cardiopathies congénitales constituaient la principale cause de décès de l’enfant, et seule-
ment une minorité de ceux nés avec une cardiopathie congénitale complexe, survivaient
et atteignaient l’âge adulte. Après l’avènement de la chirurgie cardiaque, par Lillehei en
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1953, une amélioration progressive du taux de survie a été obtenue pendant les décennies
suivantes. Cela a conduit à la situation actuelle, où le nombre de patients atteints de
cardiopathie congénitale atteignant l’âge adulte a augmenté de fac¸on progressive. Avec le
niveau actuel de soins, il est escompté que plus de 90% des patients nés avec une cardiopathie
congénitale survivront et atteindront l’âge adulte. La majorité de ces patients qui survivent
et atteignent l’âge adulte après une chirurgie cardiaque n’ont pas bénéﬁcié d’un traitement
« à vie » : la majorité en effet gardent des anomalies cardiaques résiduelles. La nécessité de la
poursuite de soins spécialisés après les années d’enfance a été soulignée depuis le début des
années 1980. L’existence de réseaux de santé pour les patients adultes atteints d’affection
cardiaque, les services usuels de soins aux cardiaques, ne sont pas adaptés à cet objectif,
du fait du manque d’expérience et donc de compétence dans ce domaine spéciﬁque. Cette
observation a conduit à établir des programmes pour des unités spécialisées dans l’Europe
entière. Certains de ces programmes ont débuté dans les années 1980, la majorité dans les
années 1990 et le nombre de centres spécialisés est en augmentation constante. De plus, le
nombre de ces centres tente à augmenter rapidement.
© 2010 Elsevier Masson SAS. Tous droits réservés.
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oongenital heart disease is the most common of all congen-
tal defects. In terms of organization of care, the emphasis
as always been on the impact of congenital heart disease
n the ﬁrst years of life: in the era before cardiac surgery,
ongenital heart disease was the most important cause of
nfant death and only a few of those born with complex
ongenital heart disease survived until adulthood. Since the
ntroduction of cardiac surgery by Lillehei in 1953, a gradual
mprovement in survival has been achieved over the subse-
uent decades. This has led to a situation where the number
f patients with congenital heart disease who reach adult
ge has gradually increased, and with the current level of
ealthcare it is expected that over 90% of babies born in
eveloped countries with congenital heart disease will now
urvive until adulthood.
Most patients who survive into adulthood after cardiac
urgery in childhood, are not ‘cured’ for life; almost all
ave residual abnormalities [1]. The need for continuation
f specialized care after their childhood years has been
mphasized since the early 1980s [2]. The existing health-
are networks for adult patients with cardiac problems — the
egular cardiology services— are not equipped for this task,
ecause of lack of training and exposure and therefore skills
n this speciﬁc ﬁeld [3]. Awareness of this issue has led to
he establishment of programmes for specialized adult con-
enital heart disease (ACHD) care throughout Europe. Some
rogrammes started in the 1980s, many in the 1990s, and
he number of centres is still increasing. In addition, existing
entres tend to grow, many of them rapidly [4].
In a recent survey, Moons et al. [5] identiﬁed 70 centres
n Europe that could be labelled as centres for ACHD. Alto-
ether, these 70 centres had some 130,000 adult patients in
heir care. The authors stated that this was only a fraction of
he entire population of patients with ACHD, that this pop-
lation is heavily under serviced in terms of available care
t an adequate level and that many more centres —or much
arger units— would be needed.Establishing and running a unit for specialized ACHD care
s, however, a costly affair, as these chronically ill patients
ith considerable morbidity [6], need a relatively large
mount of ‘‘doctor time’’ and claim a fairly large proportion
c
u
s
sf health-care resources [7]. If we want to convince health-
are planners and boards (or directors of hospitals) of the
ecessity of investing in such a costly service, we need to
nswer a few basic questions. How many patients in total are
nvolved? How many of these patients have complex ACHD,
ow many have ACHD of moderate severity and how many
ave mild ACHD? Which defects really require specialized
ertiary referral ACHD care and which can be dealt with in
egional hospitals by cardiologists? How many patients need
o special cardiac follow-up at all? These are simple and fair
uestions, but are difﬁcult to answer.
We do not know the incidence of congenital heart disease
i.e., how many patients are born per year with congenital
eart disease in a speciﬁc population or country), because
eports on this topic vary enormously from four per 1000 live
irths to 50 per 1000 live births.
We also do not know the prevalence of congenital heart
isease (i.e., how many patients are alive with congenital
eart disease in a population or country), because we do not
now the starting point (the incidence) or how many patients
ave died. We are not aware of any country in which there is
population-based registry that is solid and detailed enough
o answer these questions.
What should be considered as complex congenital heart
isease? There is no uniformity in the deﬁnition that has
een used in the various published studies, task force reports
nd position papers. For example, tetralogy of Fallot and
trioventricular septal defects —both fairly large diagnosis
roups— are defects that are classiﬁed as severe or com-
lex by some and as moderately severe by others. Neither
s there consensus about which patient group actually needs
ighly specialized, tertiary referral care. There is not much
iscussion about really complex congenital heart disease (it
s accepted that patients should be seen in a specialized
entre]) and there is also a shared belief that truly simple
esions do not need specialized care. But what is the best
ption for the group of patients with moderately complex
ongenital heart disease? Regional care provided by the reg-
lar cardiology services near the patient, tertiary referral
pecialized care, or both options as shared care? And who
hould do a catheter-based intervention or a surgical proce-
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dure in a simple defect detected in adulthood? Atrial septal
defect closure and aortic coarctation are the most typical
examples. Should they all be referred to a tertiary referral
centre?
With the major issues of incidence and prevalence largely
unresolved, and no consensus about the number and cate-
gory of patients that should be seen in a tertiary referral,
specialized ACHD centre, it is very difﬁcult to make plans to
create adequate healthcare for these patients. This proba-
bly explains the current situation in Europe regarding ACHD
care, as described by Moons et al. [5].
There have been some excellent attempts in recent years
to tackle this issue. Although based mainly on estimations
and not on actual measurements, and coming mostly from
the USA, these studies might be very helpful in trying to
understand the scope of the problem in Europe.
What is the problem with assessment of
congenital heart disease incidence?
The landmark study on this topic was published by Hoffman
and Kaplan in 2002 [8]. They reviewed 62 studies published
after 1955 on the incidence of congenital heart disease, and
found that it varied from four to 50 per 1000 live births.
This huge variation requires explanation, and Hoffman and
Kaplan provided that. In short, large, population-based stud-
ies will represent the number of live births reliably but will
rarely be able to use sophisticated screening tools for a
very high number of patients, so will probably fail to detect
all cases of congenital heart disease. This will lead to an
underestimation of the real incidence.
Smaller studies, applying sophisticated screening tools
(e.g., repeated echo studies throughout the ﬁrst months of
life), will probably detect all cases of congenital heart dis-
ease, but the population in which they are applied is often
small and therefore the outcome might not be representa-
tive of the entire population; owing to selection bias, these
studies tend to overestimate the incidence of congenital
heart disease.
The use of echocardiography is also important. Early
studies, before the mid 1980s, did not have echocardiog-
raphy as a diagnostic tool and will have missed many small
defects. However, even in later studies that applied echocar-
diography, the differences between studies remained large.
It appears that the huge variation was explained almost
exclusively by varying percentages of mild and trivial lesions
being detected.
The incidence of moderate-to-severe congenital heart
disease was similar in most studies and appeared to be rela-
tively stable for many years and in many different countries,
largely irrespective of the use of echocardiography: approxi-
mately six per 1000 live births, of which three per 1000 were
severe and three per 1000 were moderate.
Based on the meta-analysis, we may conclude that the
incidence of congenital heart disease that is relevant to the
discussion about the need for specialized ACHD care is at
least three per 1000 live births with regard to complex con-
genital heart disease, and possibly as many as six per 1000
live births if moderately severe congenital heart disease is
included.
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In a paper from the UK published in 2001, Wren and
’Sullivan [9] reviewed all conﬁrmed cardiovascular mal-
ormations diagnosed between 1985 and 1999 in children
orn in 1985 to 1994 in one health region (Newcastle, Eng-
and). The observed incidence of congenital heart disease
n infancy was 5.2 per 1000 live births. It was very interest-
ng that of all the patients diagnosed with congenital heart
isease who had a life expectancy greater than 16 years of
ge, 35% were diagnosed after the ﬁrst year of life. This
ndicates that basing the incidence of congenital heart dis-
ase on screening in the ﬁrst year of life, even in a relatively
ecent era with the beneﬁt of echocardiography, leads to a
ubstantial underestimation of the number of patients that
s relevant for the discussion about care for ACHD. Based on
he complexity of the disease (and using a slightly different
eﬁnition to Hoffman and Kaplan) they predicted that two
er 1000 live births would need specialized care for con-
enital heart disease beyond childhood. This is substantially
ower than the estimation of Hoffman and Kaplan, partly
xplained by lower detection of congenital heart disease
despite a substantial number of patients detected after the
rst year of life) and partly by the deﬁnition of which patient
ategory needs specialized care throughout life.
Two diagnoses complicate the discussion about the
ncidence of congenital heart disease: bicuspid aortic
alve (BAV; 13 per 1000 live births) [10] and congenital
itral regurgitation/stenosis, including mitral valve pro-
apse (40—50 per 1000 live births) [11]. These lesions are
ongenital and could therefore rightfully be included in
eports about incidence. In particular, BAV has a fairly high
ikelihood of needing surgical intervention during adult life.
f these lesions were included in the calculation of need for
pecialized ACHD care, the numbers (and the costs attached
o these programmes) would be greatly inﬂated. It is our
pinion that because patients with BAV and congenital mitral
tenosis/regurgitation, in considerable numbers, have been
aken care of for so long by general adult cardiologists and
urgeons (who have the necessary expertise because the
esions occur so frequently), they do not ﬁt into the cat-
gory of ACHD patients for whom specialized care should be
rranged.
We come to the conclusion that for the discussion about
ealthcare planning for ACHD and the number of patients
hat need specialized ACHD care, an incidence of at least
wo per 1000 live births should be used (Wren and O’Sullivan)
nd possibly up to six per 1000 live births (Hoffman and
aplan: combined complex and moderately severe cases).
hat is the problem with assessment of
ongenital heart disease prevalence in
urope?
here are no reliable data on the prevalence of congen-
tal heart disease in Europe. According to the deﬁnition,
revalence is the total number of patients with congenital
eart disease at a certain moment or in a deﬁned period: all
atients born with congenital heart disease minus those who
ave died. The total number of live births per year has been
egistered quite reliably in most countries for many decades.
f one assumes an incidence of complex and moderate-to-
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Table 1 Estimated number of patients with adult congenital heart disease in the USA and in six Western European
countries.
Country Population a No. of identiﬁed ACHD centres Severity of congenital heart disease
Severe Moderate Mild Total
USA 280,000,000 117,000 302,000 368,000 787,800
France 64,000,000 4 26,676 68,856 83,904 179,618
Germany 82,000,000 5 34,164 88,184 107,456 230,037
Italy 58,000,000 5 23,400 81,540 99,360 163,074
Belgium 10,000,000 4 4178 11,174 13,616 29,119
The Netherlands 16,000,000 7 6669 17,214 20,976 44,904
United Kingdom 61,000,000 12 25,536 65,836 80,224 171,566
ACHD: adult congenital heart disease.
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ia Population of USA in 2000; population of European countries in
evere congenital heart disease to be between two and six
er 1000 live births (see above), the number of patients who
ave been born with congenital heart disease in the past 60
ears, for example, can be calculated. However, we have no
eans of knowing how many patients have died. We are not
ware of any nationwide registry that has run for such a pro-
onged time, with the required high accuracy and speciﬁcity
hat could supply the necessary data.
The paucity of data on this topic has hindered the devel-
pment of ACHD all over the world. Two groups, one from
he USA and one from Canada, did excellent work in this
rea and shone some light on what was, until recently, a
ark ﬁeld.
In 2007, Marelli et al. [12] reported on measured preva-
ence of congenital heart disease in Quebec. This group were
ble to do that because every individual in Quebec obtains a
nique Medicare number, and all diagnoses and health-care
ervices rendered are recorded systematically until death.
ll patients who came into contact with the health-care sys-
em between 1983 and 2000 were entered into a congenital
eart disease database. In the year 2000, they reported a
revalence of congenital heart disease for the entire pop-
lation of 5.78 per 1000; for children, the prevalence was
1.89 per 1000 and for adults it was 4.09 per 1000. The
revalence of severe congenital heart disease was 1.45 per
000 children and 0.38 per 1000 adults. A substantial pro-
ortion of the severe lesions were not followed regularly in
centre with speciﬁc ACHD expertise [13].
Severe lesions were deﬁned as tetralogy of Fallot (and
imilar abnormalities, such as pulmonary atresia with
entricular septal defect and truncus arteriosus), atrioven-
ricular septal defect, transposition of the great arteries in
ll possible forms and univentricular hearts. This is another
eﬁnition of severe or complex congenital heart disease that
iffers from that of Hoffman and Kaplan, but is unarguably a
ist of severe malformations, with many residual abnormali-
ies and high morbidity, for which lifelong specialized ACHD
are is indicated. All other congenital heart disease lesions
that did not ﬁt into this ‘‘severe’’ category) combined had
prevalence of 10.44 per 1000 children and 3.71 per 1000
dults.
If one assumes that the socioeconomic situation in Que-
ec is largely similar to that of Western European countries
d
t
p2009.
currently and historically over the past 50 years), it might
e possible to extrapolate some of these data to calculate
atient numbers in Europe. For example, in France, with 64
illion inhabitants, this would amount to 24,300 patients
ith complex congenital heart disease and 237,440 patients
ith other forms of congenital heart disease. For the Nether-
ands, with 16 million inhabitants, it would amount to 6080
atients with severe congenital heart disease and 59,360
atients with other forms of the disease. These calculated
umbers of patients differ so much from what is known
rom clinical practice in The Netherlands, that one has to
ccept that there is either an enormous under-service for
dult congenital heart disease in The Netherlands, despite
ts high-level, highly-organized health-care system, or that
he methodology of the Quebec study has too many ﬂaws
o allow these calculations and extrapolation to the Dutch
ituation.
In 2001, the American College of Cardiology Bethesda
onference Task Force 1 presented in ‘‘The Changing Pro-
le of Congenital Heart Disease in Adult Life’’, which was
heir approach to estimating patients with ACHD in the USA
14]. Based on USA census data, the documented birth rates
rom 1940 to 1989 were averaged, enabling the total num-
er of children born in the USA in this time period to be
alculated. The incidence of CHD per 1000 live births was
erived from the available literature. As indicated above,
he choice of which study to use as the basis for the inci-
ence of congenital heart disease has greatly inﬂuenced the
ventual outcome. The survival rate for the ﬁrst year of life
nd survival until the year 2000 were estimated in a complex
ut realistic way. The time period was divided into three
hases of 20 years (1940—1959, 1960—1979 and 1980—1999)
nd the diagnoses were divided into three groups: complex,
oderate and mild. Different estimated survival rates for
he three subgroups in the three time periods led to the
utcome: an estimated 787,800 patients with ACHD alive in
he USA in the year 2000, when the USA had a population of
80,000,000 people. Of these, 117,000 had complex congen-
tal heart disease, 302,000 had moderate congenital heart
isease and 368.000 had mild lesions.
The estimation of numbers was an important mandate for
he Bethesda Conference, as it was to provide the basis of
rogramme planning and resource allocation. An extrapola-
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tion of these estimations to the Western European situation
—acknowledging all shortcomings and limitations of such
extrapolations— is shown in Table 1.
It is interesting to see that for the group of patients
with complex disease, the measured prevalence in Quebec
is similar to the estimated prevalence from the Bethesda
Conference. In contrast, the number of moderate and mild
lesions in this estimation model is substantially lower: about
50% of the measured prevalence in Quebec.
What can be said about the number of
patients with adult congenital heart
disease in Europe?
It is questionable whether the estimations and calcula-
tions of the number of patients with adult congenital heart
disease in the USA and Quebec are valid. Moreover, extrap-
olating numbers from the USA to arrive at an estimation
of the situation of ACHD in Europe can also be disputed.
There have been differences in socioeconomic situations in
the past 50 years and in accessibility to health-care systems,
and cardiac surgery for congenital heart disease was intro-
duced somewhat later in large parts of Europe compared
with in the USA. Currently, however, it is all we have, and
it can be used to make at least a rough estimation of the
situation.
For countries in the European Union, with an estimated
population of 491,582,852 [15] in July 2009 (1.75 times
the USA population in 2000), the number of patients with
complex congenital heart disease would be approximately
180,000—200,000. These patients deﬁnitely deserve special-
ized care.
For moderate congenital heart disease, the ﬁgure would
be at least 500,000 patients. One can argue whether spe-
cialized care for every patient in this category of severity
is really necessary, but most will agree that at least part of
the care for this patient group (e.g., surgical and catheter-
based interventions) should be done in specialized centres
[16].
Given that only 130,000 patients received specialized
care in one of the 70 ACHD centres that could be traced
by Moons et al., it seems obvious that we miss a large pro-
portion of the patients in the health-care system designed to
provide this care. However, we do not know whether these
patients exist in numbers similar to those in the North Amer-
ican data and estimates. If they do, we do not know who
is providing their care. General physicians? Cardiologists?
Paediatric cardiologists?
Obviously, we need more data— speciﬁcally, European
data. In our opinion, we need a European ‘‘Bethesda Confer-
ence’’, and have asked the European Society of Cardiology
to support this initiative. The aim of a European Society
of Cardiology Task Force for ACHD would be to establish
uniformity in deﬁnitions and methodologies for the inves-
tigation of the scope of the ACHD problem in Europe. An
unequivocal classiﬁcation of severity of congenital heart dis-
ease (which diagnosis belongs in which category) and which
category of patients should be looked after in which level
[415
f care (tertiary referral centre or regular adult cardiology
etting) is necessary. These deﬁnitions, together with rec-
mmendations on how to trace patients and how to calculate
stimations, can be handed over to national cardiology soci-
ties, who will have to perform the difﬁcult task of actually
nding these patients in their own country, probably in coop-
ration with national working groups in ACHD. Only when
rmed with data on how large the problem is that we have
o deal with, we do have a chance of convincing policy-
akers to allocate serious resources for ACHD, despite these
conomically difﬁcult times.
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